An Open-label Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)
Completed · Phase 2
Conditions studied: Pulmonary Aspergillosis
In brief
A study to evaluate the safety and tolerability of opelconazole for the prevention of fungal aspergillus infections in the lung in participants who have received a lung transplant.
Key facts
- Study ID
- NCT05037851
- Run by
- Pulmocide Ltd
- People needed
- 102
- Starts
- 2021-11-19
- Expected to finish
- 2023-11-13
- Last updated by the study team
- 2026-04-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Clinical Research Site — Phoenix, Arizona, United States
- Clinical Research Site — La Jolla, California, United States
- Clinical Research Site — Los Angeles, California, United States
- Clinical Research Site — Jacksonville, Florida, United States
- Clinical Research Site — Tampa, Florida, United States
- Clinical Research Site — Maywood, Illinois, United States
- Research Site — St Louis, Missouri, United States
- Clinical Research Site — New York, New York, United States
- Clinical Research Site — The Bronx, New York, United States
- Clinical Research Site — Philadelphia, Pennsylvania, United States
- Clinical Research Site — Philadelphia, Pennsylvania, United States
- Clinical Research Site — Pittsburgh, Pennsylvania, United States
- Clinical Research Site — Nashville, Tennessee, United States
- Clinical Research Site — Dallas, Texas, United States
- Clinical Research Site 1 — Houston, Texas, United States
- Clinical Research Site 2 — Houston, Texas, United States
- Clinical Research Site 3 — Houston, Texas, United States
- Clinical Research Site — Edmonton, Canada
- Clinical Research Site — Toronto, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.